News

In cataract surgery cases where implantation of a monofocal acrylic IOL is planned, a recently approved model (Akreos Advanced Optics Aspheric Lens [model AO60], Bausch & Lomb) has rapidly become the IOL of choice for one surgeon who has implanted almost 100 of the lenses.

Anatomic outcomes of penetrating keratoplasty (PKP) have improved thanks to a number of innovations, but functional outcomes have still been suboptimal. The development of techniques based on use of the femtosecond laser to create host and donor incisions has driven PKP into a new era of refractive surgery.

An eye model was used to evaluate image quality associated with different available multifocal IOLs. The overall results show benefits of an aspheric apodized diffractive design.

A proprietary toric IOL (AcrySof Toric, Alcon Laboratories) was found to be rotationally stable and a reliable option for the correction of astigmatism in a prospective study of 50 patients. The results were arrived at by using an innovative digital imaging technique coupled with new software that uses a grid to determine rotational stability of IOLs to a sensitivity of 0.1°. The implications of the new digital imaging technology and its associated software extend well beyond the findings in these 50 patients.

A mechanical microkeratome (One Use-Plus SBK, Moria) created flaps with predictable dimensions that were planar and associated with extremely smooth stromal beds, and patients benefited with rapid visual recovery, in a clinical trial including 50 eyes as well as cadaveric eyes. The microkeratome was compared with a 60-kHz femtosecond laser (IntraLase, Advanced Medical Optics) in the study.

An analysis of outcomes in 1,088 eyes treated using a nomogram developed at the University of Rochester highlights its excellent performance in improving treatment accuracy.

An aspheric implant (Acri.LISA Toric 466 TD IOL, Carl Zeiss Meditec) corrects astigmatism and presbyopia and can be implanted through a >1.5-mm incision to avoid surgically induced astigmatism and minimize induced aberrations. The optic is designed for optimal visual quality and the haptics for rotational stability. Excellent outcomes, including high patient satisfaction, have been achieved implanting this IOL after co-axial microincisional surgery using a phacoemulsification platform (Oertli).

Mixing and matching IOLs with different optical principles was investigated in a European multicenter project. Data from 90 patients seen at 120 to 180 days after surgery showed excellent results in functional outcomes, patient satisfaction, and spectacle independence.

Five femtosecond lasers are now commercially available. They vary in their features and capabilities, but the product category as a whole is characterized by a rapid evolution toward improved technology with more changes and a growing list of uses expected in the future.

Skillful physician-patient communication is paramount to successful prevention and management of dissatisfied LASIK patients.

The angle-supported phakic IOL (AcrySof, Alcon Laboratories) is being evaluated for the treatment of moderate to high myopia in three phase II and III clinical trials in Europe and North America enrolling 360 patients. Data from a 3-year visit in 104 eyes show excellent stability, predictability, and vision outcomes with a low rate of adverse events.

Results of the 2008 International Society of Refractive Surgery/American Academy of Ophthalmology survey are consistent with market data showing a decline in the number of patients undergoing refractive surgery, but they demonstrate surgeon confidence in the procedure, with 35% of respondent surgeons having undergone LASIK or PRK in their own eyes. Use of the femtosecond laser for flap creation and preferences for thinner flaps and phakic IOLs for treating high myopia are growing.

Eye disease and sleep disorders are linked in several ways, according to research published recently in Mayo Clinic Proceedings.

Eye disease and sleep disorders are linked in several ways, according to research published recently in Mayo Clinic Proceedings.

Vision Research Center has launched a research Web site (www.visionresearchcenter.com) where experts in the ophthalmic community and patients can share their experiences and opinions concerning technology and therapies, according to a prepared statement.

A team of seven leading ophthalmologists has been assembled to evaluate the accommodative properties of a proprietary material (Collamer, STAAR Surgical) used in the company's accommodating IOLs, it was announced in a prepared statement.

Eschenbach Optik has been named the exclusive North American distributor of the Ash Technologies Ltd. line of video magnification products.

Alcon Inc. has launched an online educational resource, www.cataractsurgery.com, for people who have cataracts, and their caregivers.

Abu Dhabi, the capital of the United Arab Emirates, will be the site of the World Ophthalmology Congress (WOC) meeting in February 2012.

We live in a connected world thanks in part to former Vice President and Nobel Peace Prize winner Al Gore. Dr. McDonnell shares his ambitions for the New Year: to rival Al Gore and win the Nobel Peace Prize in Literature.

A national prospective study is being planned to evaluate post-LASIK quality of life outcomes in a clinical setting. The trial is being coordinated by representatives from the FDA, the National Eye Institute (NEI), the American Society of Cataract & Refractive Surgery, and the American Academy of Ophthalmology, and it will be executed in accordance with the rules governing FDA and NEI clinical trials.

Intracameral injection of triamcinolone is very useful for "staining" vitreous that has prolapsed into the anterior segment to enable vitrectomy. Safety is favorable, but there are some issues to consider.

Posterior capsule rupture with vitreous prolapse remains one of the most serious intraoperative complications during cataract surgery. Louis D. "Skip" Nichamin, MD, describes the benefits and technique for anterior vitrectomy using a pars plana approach.

Although retinal detachments puts an individual at risk for vision loss or blindness, a new study published in the New England Journal of Medicine showed that a high probability of reattachment and visual improvement is possible by using one of the three currently available surgical techniques.

A new adjunctive treatment (Diamox, X-GEN Pharmaceuticals) is being marketed for open-angle glaucoma, secondary glaucoma, and preoperatively acute angle-closure glaucoma where delay of surgery is desired in order to lower IOP.

See by Three, a program of the Children's Eye Foundation, has completed the first phase of its national research project to advocate effective screening of children for amblyopia so they will "see by three".

A world market research report is now available for IOLs through Reportlinker.com.

People with cataract-induced visual impairment are more likely to live in poverty than those with normal sight, according to a study conducted in three developing countries-Kenya, the Philippines, and Bangladesh.